Serum proteomic profiling for the early diagnosis of colorectal cancer

Journal of Cellular Biochemistry

Volumn 114, Issue 2, 2013, Pages 448-455

  Zhu, Dexiang ^a   Wang, Jie ^b   Ren, Li ^a   Li, Yan ^b,c   Xu, Bin ^b   Wei, Ye ^a   Zhong, Yunshi ^a   Yu, Xinzhe ^a   Zhai, Shenyong ^a   Xu, Jianmin ^a   Qin, Xinyu ^a  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

^c Bioyong (Beijing) Technology Co Ltd   (China)

Author keywords

Colorectal cancer; Maldi TOF MS; Proteomics; Serum peptides

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3F; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; AMINO ACID SEQUENCE; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; EXTERNAL VALIDITY; FEMALE; HUMAN; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MAGNET; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MODEL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

BLOOD PROTEINS; COLORECTAL NEOPLASMS; COMPLEMENT C3B; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84872692906     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24384     Document Type: Article

References (31)

1. Ajona D, Castaño Z, Garayoa M, Zudaire E, Pajares MJ, Martinez A, Cuttitta F, Montuenga LM, Pio R. 2004. Expression of complement factor H by lung cancer cells: Effects on the activation of the alternative pathway of complement. Cancer Res 64:6310-6318.
2. Albrethsen J. 2007. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 53:852-858.
3. An Y, Bekesova S, Edwards N, Goldman R. 2010. Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma. Dis Markers 29:11-20.
4. Anderson NL, Anderson NG. 2002. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1:845-867.
5. Chang JT, Chen LC, Wei SY, Chen YJ, Wang HM, Liao CT, Chen IH, Cheng AJ. 2006. Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry-plasma peptidomes from nasopharyngeal cancer patients for example. Clin Biochem 39:1144-1151.
6. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT, Chen IH. 2005. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 51:2236-2244.
7. de Noo ME, Tollenaar RA, Deelder AM, Bouwman LH. 2006. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: Hopes and fears. World J Gastroenterol 12:6594-6601.
8. Duffy MJ. 2001. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem 47(4):624-630.
9. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. 2007. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43:1348-1360.
10. Ebert MP, Niemeyer D, Deininger SO, Wex T, Knippig C, Hoffmann J, Sauer J, Albrecht W, Malfertheiner P, Röcken C. 2006. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res 5:2152-2158.
11. Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack B, Jr., Schraff S, Semmes OJ, Wadsworth JT, Drake RR. 2008. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope 118: 61-68.
12. Gemoll T, Roblick UJ, Auer G, Jörnvall H, Habermann JK. 2010. SELDI-TOF serum proteomics and colorectal cancer: A current overview. Arch Physiol Biochem 116:188-196.
13. Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJ, Podust VN, Roman JM, Oevermann E, Schiedeck T, Homann N, Duchrow M, Conrads TP, Veenstra TD, Burt SK, Bruch HP, Auer G, Ried T. 2006. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131:1020-1029.
14. Hanash SM, Baik CS, Kallioniemi O. 2011. Emerging molecular biomarkers- blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 8:142-150.
15. Huijbers A, Velstra B, Dekker TJ, Mesker WE, van der Burgt YE, Mertens BJ, Deelder AM, Tollenaar RA. 2010. Proteomic serum biomarkers and their potential application in cancer screening programs. Int J Mol Sci 11:4175-4193.
16. Ishida Y, Yamashita K, Sasaki H, Takajou I, Kubuki Y, Morishita K, Tsubouchi H, Okayama A. 2008. Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: A serum proteomic approach using mass spectrometry. Cancer Lett 271:167-177.
17. Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics. CA Cancer J Clin 60:277-300.
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69-90.
19. Jimenez CR, Knol JC, Meijer GA, Fijneman RJ. 2010. Proteomics of colorectal cancer: Overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics 73:1873-1895.
20. Liang T, Wang N, Li W, Li A, Wang J, Cui J, Liu N, Li Y, Li L, Yang G, Du Z, Li D, He K, Wang G. 2010. Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics 10:90-98.
21. Okroj M, Hsu YF, Ajona D, Pio R, Blom AM. 2008. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45:169-179.
22. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, Petricoin EF III, Liotta LA. 2004. Serum proteomics in cancer diagnosis and management. Annu Rev Med 55:97-112.
23. Rozanov DV, Savinov AY, Golubkov VS, Postnova TI, Remacle A, Tomlinson S, Strongin AY. 2004. Cellular membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system. J Biol Chem 279:46551-46557.
24. Rozen P. 2004. Cancer of the gastrointestinal tract: Early detection or early prevention? Eur J Cancer Prev 13:71-75.
25. Sahu A, Lambris JD. 2001. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180:35-48.
26. Schwamborn K, Krieg RC, Grosse J, Reulen N, Weiskirchen R, Knuechel R, Jakse G, Henkel C. 2009. Serum proteomic profiling in patients with bladder cancer. Eur Urol 56:989-996.
27. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. 2006. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284.
28. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P. 2008. A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol Cell Proteomics 7:509-518.
29. Wang N, Dong FT, Zhang XM, Li AL, Wang J, Wang HX, Li P, Wu SM, Yang XH. 2007. Hydrothermal synthesis of metal-chelated magnetic nanobeads for exclusive use of peptides extraction by mass spectrum. Acta Chim Sin 65:344-348.
30. Wang Q, Shen J, Li ZF, Jie JZ, Wang WY, Wang J, Zhang ZT, Li ZX, Yan L, Gu J. 2009. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 9:287.
31. Wulfkuhle JD, Liotta LA, Petricoin EF. 2003. Proteomic applications for the early detection of cancer. Nat Rev Cancer 3:267-275.